CJC-1295 DAC

Price and cost-per-mg comparison

CJC-1295 DAC (also written DAC-GRF) is a synthetic 30-amino-acid growth hormone-releasing hormone (GHRH) analog incorporating a Drug Affinity Complex (DAC) — a trans-4-aminomethylcyclohexane carboxylic acid group — that enables covalent binding to circulating albumin. This albumin binding is the defining feature of the DAC variant: it extends the plasma half-life from the minutes characteristic of native GHRH and short-acting analogs to approximately 6–8 days, and is the pharmacological basis for the less-frequent administration schedules described in the research literature. Because of this sustained exposure, CJC-1295 DAC acts as a prolonged GHRH-receptor agonist at pituitary somatotrophs rather than producing the brief, pulsatile stimulation of its non-DAC counterpart, and has been studied in the context of growth hormone axis support. The distinction between the DAC and non-DAC forms is central. The non-DAC form — commonly called Mod GRF 1-29 or CJC-1295 without DAC — lacks the albumin-binding complex and has an effective half-life measured in minutes, producing short, discrete GH pulses. The DAC form's multi-day half-life instead produces a prolonged elevation of GHRH-receptor signaling. Researchers describe these as different pharmacokinetic tools rather than interchangeable versions of one compound, which is why PeptideBase catalogs them as separate records. The indexed human evidence base for CJC-1295 DAC is limited. A single Phase 1 dose-escalation, randomized controlled trial in healthy adults, published in the Journal of Clinical Endocrinology & Metabolism (2006), reported dose-dependent and sustained increases in mean GH and IGF-1 concentrations after single-dose administration; the remaining indexed literature consists largely of anti-doping detection methods. CJC-1295 DAC has no FDA approval and no approved therapeutic indication in any jurisdiction — it is available only as a research compound, and no Phase 2 or Phase 3 efficacy data exists for any specific application. Content here is educational and for research context only; it is not medical, dosing, or treatment guidance. [Women's health addendum] As with unmodified CJC-1295, no controlled human data exist for CJC-1295 DAC in any women's-health context, and no human pregnancy/lactation safety data exist for this unapproved research compound.

46 listings · 30 vendors · updated 28 Sept 2026 · how prices are computed · educational only, not medical advice